Regulatory Investigation Risk in Life Sciences: Act Early to Protect Your Business

When an agency issues a CID or subpoena, the recipient faces a narrow window to assert objections. Overbroad demands, requests for privileged material, or inquiries seeking information outside the agency's statutory mandate can be challenged in federal court, but the burden on the recipient is steep. Courts generally defer to agency determinations of relevance. In practice, these challenges rarely succeed unless the demand seeks attorney-client communications or work product protected from disclosure. The practical risk is that objecting too broadly signals weakness and may invite judicial review that validates the agency's position and narrows the recipient's negotiating leverage.

Life sciences investigations often originate from adverse event reports, whistleblower disclosures, or patterns flagged in claims data. A single serious adverse event may not trigger enforcement; regulatory agencies typically look for systemic failures, repeated violations, or evidence of knowledge and deliberate indifference. From a practitioner's perspective, the early forensic review of internal communications, testing protocols, and quality assurance records is essential. Courts and juries expect companies to have identified and corrected problems; failure to do so, even absent explicit knowledge, can support negligence and regulatory violation findings.

Communications between in-house counsel and business personnel are privileged if made for the purpose of obtaining legal advice. However, the privilege is easily lost if the communication is shared with non-legal personnel or if the primary purpose is business advice rather than legal guidance. In investigations, agencies often seek communications about compliance decisions, risk assessments, and remediation efforts. If those communications are framed as business decisions rather than legal advice, privilege may not attach. The practical approach is to ensure that compliance inquiries are routed through counsel and documented as seeking legal advice. Investigative reports prepared by outside counsel at the request of in-house counsel for litigation purposes may qualify as work product, but this protection is qualified and can be pierced if the recipient shows substantial need and inability to obtain equivalent information through other means.

New York State maintains its own pharmacy board, medical board, and state health department enforcement mechanisms. When federal and state investigations proceed in parallel, discovery obligations in New York state court proceedings may differ from federal practice. New York CPLR 3101 permits broad discovery of information relevant to the subject matter of the action. State court judges often require earlier and more extensive disclosure than federal courts. If a defendant faces both federal criminal charges and state regulatory proceedings, counsel must coordinate discovery positions carefully to avoid waiving privilege or creating inconsistencies that undermine credibility.

The False Claims Act defines knowingly to include actual knowledge, deliberate ignorance, and reckless disregard for the truth. A company need not intend to defraud; negligent submission of a false claim can suffice if the company acted with reckless disregard. This lower bar creates exposure even for companies that believed their conduct was compliant. In one representative scenario, a pharmaceutical manufacturer marketed a drug for an indication not approved by the FDA; sales representatives distributed materials to physicians describing the off-label use. The company argued that individual physician prescribing decisions were not false claims because the physicians, not the company, submitted the claims. Courts rejected this argument, finding that the company's marketing conduct constituted knowing submission of false claims through intermediaries.

Life sciences investigations frequently examine relationships between manufacturers and healthcare providers. The Anti-Kickback Statute prohibits remuneration offered to induce referrals or recommendations. The Stark Law prohibits physicians from referring patients to entities with which they have a financial relationship, absent a safe harbor. These statutes overlap but operate independently. A payment arrangement that violates the Anti-Kickback Statute may also implicate Stark Law and generate False Claims Act liability if it results in claims submitted to federal programs. The interplay creates compounding exposure and requires careful structuring of manufacturer-provider relationships, including speaker programs, consulting arrangements, and research funding.

Life sciences investigations often target individuals, including executives, scientists, and compliance officers. Criminal charges may include wire fraud, mail fraud, conspiracy, and False Claims Act violations. Individual defendants face potential imprisonment, personal liability for restitution, and professional licensure consequences. A company that settles civilly may not shield individual executives from criminal prosecution. Defense strategy must distinguish between corporate and individual exposure early and consider whether cooperation or separate representation is appropriate.

Beyond civil and criminal penalties, life sciences enforcement can trigger exclusion from federal programs, debarment from federal contracts, and loss of professional licenses. The Office of Inspector General maintains the List of Excluded Individuals and Entities (LEIE); exclusion is published and affects employment, contracting, and business operations. State medical and pharmacy boards may initiate parallel disciplinary proceedings. Counsel must evaluate the collateral consequences alongside the direct financial exposure and factor them into settlement negotiations and trial strategy.